[CLVS] Clovis Oncology, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 533.24 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 45.35 Change: 0.32 (0.71%)
Ext. hours: Change: 0 (0%)

chart CLVS

Refresh chart

Strongest Trends Summary For CLVS

CLVS is in the medium-term down -62% in 1 month and down -82% below S&P in 5 months. In the long-term down -95% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has three clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; rucaparib, an oral inhibitor of poly polymerase that is being explored in Phase II or III clinical trials for treating ovarian cancer patients, and Phase II clinical trials for treating pancreatic cancer patients; and lucitanib, an oral inhibitor of the tyrosine kinase Phase I/IIa clinical trials for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements w

Fundamental Ratios
Shares Outstanding38.39 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV2.11 Price/Cash Per Share
Price/Free Cash Flow-4.47 ROA-27.31% ROE-76.19% ROI
Current Ratio7.93 Quick Ratio Long Term Debt/Equity Debt Ratio0.22
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.19 M Cash From Investing Activities-143.03 M Cash From Operating Activities-48.41 M Gross Profit
Net Profit-63.14 M Operating Profit-64.22 M Total Assets704.71 M Total Current Assets441.7 M
Total Current Liabilities55.68 M Total Debt287.5 M Total Liabilities452.12 M Total Revenue
Technical Data
High 52 week46.01 Low 52 week5.68 Last close5.68 Last change-2.57%
RSI21.21 Average true range0.92 Beta1.33 Volume1.42 M
Simple moving average 20 days-44.43% Simple moving average 50 days-54.86% Simple moving average 200 days-70.27%
Performance Data
Performance Week-38.66% Performance Month-57.1% Performance Quart-70.54% Performance Half-77.57%
Performance Year-83.79% Performance Year-to-date-68.37% Volatility daily9.98% Volatility weekly22.31%
Volatility monthly45.72% Volatility yearly158.38% Relative Volume1318.58% Average Volume2.36 M
New High New Low

News

2019-08-19 10:15:02 | Clovis Oncology Inc CLVS President and CEO Patrick J Mahaffy Bought $279,500 of Shares

2019-08-18 10:18:44 | Who Has Been Buying Clovis Oncology, Inc. NASDAQ:CLVS Shares?

2019-08-13 10:58:59 | AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis

2019-08-08 23:56:00 | 3 Stocks That Are Absurdly Cheap Right Now

2019-08-08 18:26:00 | Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes

2019-08-07 16:10:00 | Clovis Oncology to Offer $225 Million of Convertible Senior Notes

2019-08-04 17:18:24 | Edited Transcript of CLVS earnings conference call or presentation 1-Aug-19 12:30pm GMT

2019-08-02 10:04:02 | Clovis CLVS Q2 Earnings & Sales Lag Estimates, Shares Down

2019-08-02 06:24:07 | Clovis Oncology CLVS Q2 2019 Earnings Call Transcript

2019-08-01 13:11:15 | Here's Why Clovis Oncology Stock Fell as Much as 15.6% Today

2019-07-25 10:33:02 | Will Clovis Oncology CLVS Report Negative Earnings Next Week? What You Should Know

2019-07-24 09:00:01 | What's in the Cards for Zynerba ZYNE This Earnings Season?

2019-07-18 08:00:00 | Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1

2019-07-16 10:51:02 | Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study

2019-07-12 15:18:34 | Does Clovis Oncology, Inc. NASDAQ:CLVS Have A Particularly Volatile Share Price?

2019-07-02 08:37:12 | Do Options Traders Know Something About Clovis CLVS Stock We Don't?

2019-06-24 08:33:12 | Pfizer's Talzenna Gets Approval in Europe for Breast Cancer

2019-06-18 08:59:12 | AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use

2019-06-18 08:02:22 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-06-14 08:07:22 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-06-13 11:51:30 | Is Clovis Oncology Inc CLVS A Good Stock To Buy?

2019-06-13 08:04:52 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-06-11 08:06:00 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-06-10 08:07:14 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-06-07 07:24:33 | The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

2019-06-06 16:05:00 | Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair

2019-06-06 09:31:01 | Why Is Clovis CLVS Down 25.3% Since Last Earnings Report?

2019-06-06 08:07:07 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-06-04 08:05:46 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-06-01 07:30:00 | Expanded Rubraca® Rucaparib Data from Clovis Oncology’s ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting

2019-05-29 16:23:31 | Biotech Stocks Clobbered As Two Slammed With Sell Ratings

2019-05-29 10:08:00 | Clovis Oncology Stock Sinks on Dim View of Cancer Drug Sales

2019-05-20 16:05:00 | Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca®? in Advanced Ovarian Cancer

2019-05-16 08:00:00 | Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting

2019-05-08 19:33:45 | Edited Transcript of CLVS earnings conference call or presentation 7-May-19 12:30pm GMT

2019-05-08 09:46:01 | Clovis CLVS Q1 Earnings Top Estimates, Rubraca Sales Strong

2019-05-08 05:23:41 | Clovis Oncology CLVS Q1 2019 Earnings Call Transcript

2019-05-07 09:15:01 | Clovis Oncology CLVS Reports Q1 Loss, Tops Revenue Estimates

2019-05-07 08:09:26 | Clovis: 1Q Earnings Snapshot

2019-05-07 08:00:00 | Clovis Oncology Announces First Quarter 2019 Operating Results

2019-05-06 16:13:08 | Soleno Therapeutics SLNO to Post Q1 Earnings: What's Up?

2019-05-06 15:06:07 | What's in the Cards for Perrigo PRGO This Earnings Season?

2019-05-06 11:42:03 | Cronos CRON to Report Q1 Earnings: What's in the Cards?

2019-05-06 08:00:00 | Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2019

2019-05-03 10:12:45 | Here’s What Hedge Funds Think About About Clovis Oncology Inc CLVS

2019-05-02 08:00:00 | Clovis Oncology Enters into Non-Dilutive Clinical Trial Financing with TPG Sixth Street Partners for up to $175 Million

2019-04-30 10:32:02 | Clovis Oncology CLVS Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2019-04-30 08:04:56 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-04-25 14:58:48 | What Are Analysts Saying About The Future Of Clovis Oncology, Inc.'s NASDAQ:CLVS?

2019-04-24 16:05:00 | Clovis Oncology to Announce First Quarter 2019 Financial Results and Host Webcast Conference Call on May 7